Literature DB >> 12585689

Effect of melatonin on changes in locomotor activity rhythm of Syrian hamsters injected with beta amyloid peptide 25-35 in the suprachiasmatic nuclei.

Analía M Furio1, Rodolfo A Cutrera, Víctor Castillo Thea, Santiago Pérez Lloret, Patricia Riccio, Roberto L Caccuri, Luis L Brusco, Daniel P Cardinali.   

Abstract

1. Alzheimer's disease is associated with circadian rhythm disturbances, probably because of beta amyloid-induced neuronal damage of hypothalamic suprachiasmatic nuclei (SCN). 2. Since there is no published study on the circadian consequences of injecting beta amyloid peptide in experimental animals, one objective of the present study was to examine circadian locomotor activity in Syrian hamsters injected with beta amyloid peptide 25-35 into both SCN. 3. Because one of the proposed therapies for circadian alterations in dementia is the administration of melatonin, a chronobiotic agent with antioxidant properties, the preventive effect of melatonin on the circadian changes produced by beta amyloid microinjection into SCN was also assessed. 4. Wheel running activity was recorded by using the Dataquest III system in male golden hamsters kept under 14:10 light-dark photoperiods. Animals received microinjections of beta amyloid peptide 25-35 (100 microM solution, 1 microL) or saline in each SCN. Only those animals with neuronal lesions larger than 10% of SCN after beta amyloid injection were considered for further analysis. 5. To assess the effect of melatonin on beta-amyloid peptide activity, melatonin was given in the drinking water (25 microg/mL) starting 15 days in advance to the microinjection of beta amyloid peptide into SCN. 6. Beta amyloid-treated hamsters exhibited a significant phase advance of onset of running activity of about 22 min as compared to saline-injected animals. They also showed a significantly greater variability in onset time of wheel running activity, mainly evident from 6 to 15 days of treatment. 7. Melatonin administration in the drinking water prevented the phase advance of onset time and the increased variability of onset time brought about by beta amyloid peptide. 8. The results support the existence of a neuroprotective effect of melatonin on beta amyloid-induced circadian changes in hamsters.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12585689     DOI: 10.1023/a:1021805023906

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  45 in total

1.  Monozygotic twins with Alzheimer's disease treated with melatonin: Case report.

Authors:  L I Brusco; M Márquez; D P Cardinali
Journal:  J Pineal Res       Date:  1998-12       Impact factor: 13.007

2.  Circadian rhythm-related behavioral disturbances and structural hypothalamic changes in Alzheimer's disease.

Authors:  W J Hoogendijk; E J van Someren; M Mirmiran; M A Hofman; P J Lucassen; J N Zhou; D F Swaab
Journal:  Int Psychogeriatr       Date:  1996       Impact factor: 3.878

3.  A double blind-placebo controlled study on melatonin efficacy to reduce anxiolytic benzodiazepine use in the elderly.

Authors:  Daniel P Cardinali; Elisa Gvozdenovich; Marcos R Kaplan; Isidoro Fainstein; Hugo A Shifis; Santiago Pérez Lloret; Liliana Albornoz; Armando Negri
Journal:  Neuro Endocrinol Lett       Date:  2002-02       Impact factor: 0.765

4.  Inhibition of PC12 cell redox activity is a specific, early indicator of the mechanism of beta-amyloid-mediated cell death.

Authors:  M S Shearman; C I Ragan; L L Iversen
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

5.  Differential circadian rhythm disturbances in men with Alzheimer disease and frontotemporal degeneration.

Authors:  D G Harper; E G Stopa; A C McKee; A Satlin; P C Harlan; R Goldstein; L Volicer
Journal:  Arch Gen Psychiatry       Date:  2001-04

6.  Assessment and Management of "Sundowning" Phenomena.

Authors: 
Journal:  Semin Clin Neuropsychiatry       Date:  1997-04

7.  Basic aspects of melatonin action.

Authors:  D P Cardinali; P Pévet
Journal:  Sleep Med Rev       Date:  1998-08       Impact factor: 11.609

8.  Chrono-neuroendocrinological aspects of physiological aging and senile dementia.

Authors:  D Dori; G Casale; S B Solerte; M Fioravanti; G Migliorati; G Cuzzoni; E Ferrari
Journal:  Chronobiologia       Date:  1994 Jan-Jun

9.  Ca2+ channel blockers attenuate beta-amyloid peptide toxicity to cortical neurons in culture.

Authors:  J H Weiss; C J Pike; C W Cotman
Journal:  J Neurochem       Date:  1994-01       Impact factor: 5.372

10.  Effects of melatonin in two individuals with Alzheimer's disease.

Authors:  G Jean-Louis; F Zizi; H von Gizycki; H Taub
Journal:  Percept Mot Skills       Date:  1998-08
View more
  10 in total

Review 1.  Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes.

Authors:  Seithikurippu R Pandi-Perumal; Ahmed S BaHammam; Gregory M Brown; D Warren Spence; Vijay K Bharti; Charanjit Kaur; Rüdiger Hardeland; Daniel P Cardinali
Journal:  Neurotox Res       Date:  2012-06-28       Impact factor: 3.911

Review 2.  Role of melatonin in neurodegenerative diseases.

Authors:  V Srinivasan; S R Pandi-Perumal; G Jm Maestroni; A I Esquifino; R Hardeland; D P Cardinali
Journal:  Neurotox Res       Date:  2005       Impact factor: 3.911

3.  Therapeutic application of melatonin in mild cognitive impairment.

Authors:  Daniel P Cardinali; Daniel E Vigo; Natividad Olivar; María F Vidal; Analía M Furio; Luis I Brusco
Journal:  Am J Neurodegener Dis       Date:  2012-11-18

Review 4.  Novel putative mechanisms to link circadian clocks to healthy aging.

Authors:  Aurel Popa-Wagner; Bogdan Catalin; Ana-Maria Buga
Journal:  J Neural Transm (Vienna)       Date:  2013-12-03       Impact factor: 3.575

5.  Melatonin and its agonist ramelteon in Alzheimer's disease: possible therapeutic value.

Authors:  Venkatramanujam Srinivasan; Charanjit Kaur; Seithikurippu Pandi-Perumal; Gregory M Brown; Daniel P Cardinali
Journal:  Int J Alzheimers Dis       Date:  2010-12-08

6.  Clinical aspects of melatonin intervention in Alzheimer's disease progression.

Authors:  Daniel P Cardinali; Analía M Furio; Luis I Brusco
Journal:  Curr Neuropharmacol       Date:  2010-09       Impact factor: 7.363

7.  Melatonin in Alzheimer's disease and other neurodegenerative disorders.

Authors:  V Srinivasan; S R Pandi-Perumal; D P Cardinali; B Poeggeler; R Hardeland
Journal:  Behav Brain Funct       Date:  2006-05-04       Impact factor: 3.759

Review 8.  Melatonin Therapy in Patients with Alzheimer's Disease.

Authors:  Daniel P Cardinali; Daniel E Vigo; Natividad Olivar; María F Vidal; Luis I Brusco
Journal:  Antioxidants (Basel)       Date:  2014-04-10

Review 9.  Mechanisms of Melatonin in Alleviating Alzheimer's Disease.

Authors:  Mayuri Shukla; Piyarat Govitrapong; Parichart Boontem; Russel J Reiter; Jutamaad Satayavivad
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

Review 10.  Synchronizing an aging brain: can entraining circadian clocks by food slow Alzheimer's disease?

Authors:  Brianne A Kent
Journal:  Front Aging Neurosci       Date:  2014-09-01       Impact factor: 5.750

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.